uniQure N.V. (QURE) Cut to “Hold” at Zacks Investment Research
Zacks Investment Research lowered shares of uniQure N.V. (NASDAQ:QURE) from a buy rating to a hold rating in a research report sent to investors on Friday morning.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
QURE has been the subject of a number of other research reports. ValuEngine upgraded shares of uniQure N.V. from a sell rating to a hold rating in a research note on Monday, July 24th. Evercore ISI assumed coverage on shares of uniQure N.V. in a research note on Tuesday, November 7th. They issued an outperform rating and a $22.00 price target for the company. Leerink Swann lifted their price target on shares of uniQure N.V. from $17.00 to $19.00 and gave the stock an outperform rating in a research note on Friday, October 20th. Finally, Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the stock a buy rating in a research note on Sunday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $17.43.
uniQure N.V. (QURE) opened at $15.19 on Friday. uniQure N.V. has a 12-month low of $4.72 and a 12-month high of $21.35. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/uniqure-n-v-qure-cut-to-hold-at-zacks-investment-research/1702437.html.
Several institutional investors have recently added to or reduced their stakes in QURE. Mangrove Partners bought a new position in shares of uniQure N.V. during the second quarter worth about $247,000. JPMorgan Chase & Co. grew its position in shares of uniQure N.V. by 50.5% during the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 14,702 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in uniQure N.V. in the third quarter worth about $399,000. Paloma Partners Management Co lifted its holdings in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after purchasing an additional 74,605 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after purchasing an additional 122,700 shares during the period. Institutional investors and hedge funds own 24.91% of the company’s stock.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.